CCJ Stock Analysis: Cameco | NYSE
Uranium | NYSE, USA | Market Cap: 42.046m USD | 12M Return: 31.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 334M
EPS Trend: 80.9%
Qual. Beats: 1
Rev. Trend: 96.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cameco Corporation (NYSE: CCJ) is a Canadian-based uranium producer supplying fuel for nuclear power generation across the Americas, Europe, and Asia. The company operates through three segments: Uranium (exploration, mining, milling, and sale of uranium concentrate), Fuel Services (refining, conversion, and fabrication of uranium concentrate and conversion services), and Westinghouse (a nuclear reactor technology original equipment manufacturer offering outage and maintenance, engineering support, instrumentation and controls, plant modification services, and reactor components). Customers are primarily nuclear utilities, with additional sales to government agencies. Cameco was incorporated in 1987 and is headquartered in Saskatoon, Canada, with its shares listed on the NYSE since 1996.
The companys vertically integrated structure spans the front-end of the nuclear fuel cycle, from raw uranium concentrate through refined and fabricated fuel products, alongside reactor technology and services. Nuclear power provides a low-carbon baseload energy source, and Camecos inclusion in the GICS Energy sector reflects its role in fuel production rather than electricity generation itself.
- Uranium spot prices surge on AI-driven nuclear power demand
- Westinghouse acquisition expands reactor services revenue stream
- Russian uranium import ban tightens Western utility supply
| Net Income: 650.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 5.96 > 1.0 |
| NWC/Revenue: 30.71% < 20% (prev 28.73%; Δ 1.98% < -1%) |
| CFO/TA 0.18 > 3% & CFO 1.28b > Net Income 650.7m |
| Net Debt (202.1m) to EBITDA (1.20b): 0.17 < 3 |
| Current Ratio: 3.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (435.6m) vs 12m ago 0.03% < -2% |
| Gross Margin: 29.83% > 18% (prev 26.31%; Δ 3.52% > 0.5%) |
| Asset Turnover: 42.49% > 50% (prev 35.08%; Δ 7.41% > 0%) |
| Interest Coverage Ratio: 11.50 > 6 (EBIT TTM 887.3m / Interest Expense TTM 77.1m) |
| A: 0.15 (Total Current Assets 1.61b - Total Current Liabilities 522.7m) / Total Assets 7.27b |
| B: 0.37 (Retained Earnings 2.69b / Total Assets 7.27b) |
| C: 0.11 (EBIT TTM 887.3m / Avg Total Assets 8.32b) |
| D: 2.32 (Book Value of Equity 5.08b / Total Liabilities 2.19b) |
| Altman-Z'' = 5.34 = AAA |
| DSRI: 0.70 (Receivables 140.4m/185.4m, Revenue 3.54b/3.29b) |
| GMI: 0.88 (GM 26.31% / 29.83%) |
| AQI: 0.91 (AQ_t 0.45 / AQ_t-1 0.49) |
| SGI: 1.07 (Revenue 3.54b / 3.29b) |
| TATA: -0.09 (NI 650.7m - CFO 1.28b) / TA 7.27b) |
| Beneish M = -3.39 (Cap -4..+1) = AA |
As of July 05, 2026, the stock is trading at USD 96.54 with a total of 3,810,900 shares traded. Over the past week, the price has changed by -6.80%, over one month by -15.73%, over three months by -12.62% and over the past year by +31.69%.
Current recommended Stop Loss: 88.80 (which is 8% or 1.4 ATR below the current price).
Cameco has received a consensus analysts rating of 4.53. Therefore, it is recommended to buy CCJ.
- StrongBuy: 10
- Buy: 9
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 132.6 | 37.4% |
Market Cap CAD = 59.7b (42.0b USD * 1.4194 USD.CAD)
P/E Trailing = 91.9429
P/E Forward = 88.4956
P/S = 11.8847
P/B = 8.5241
P/EG = 1.9161
Revenue TTM = 3.54b CAD
EBIT TTM = 887.3m CAD
EBITDA TTM = 1.20b CAD
Long Term Debt = 996.5m CAD (from longTermDebt, last quarter)
Short Term Debt = 3.34m CAD (from shortTermDebt, last fiscal year)
Debt = 999.9m CAD (corrected: LT Debt 996.5m + ST Debt 3.34m)
Net Debt = 202.1m CAD (calculated: Debt 999.9m - CCE 797.8m)
Enterprise Value = 59.9b CAD (59.7b + Debt 999.9m - CCE 797.8m)
Interest Coverage Ratio = 11.50 (Ebit TTM 887.3m / Interest Expense TTM 77.1m)
EV/FCF = 64.97x (Enterprise Value 59.9b / FCF TTM 921.7m)
FCF Yield = 1.54% (FCF TTM 921.7m / Enterprise Value 59.9b)
FCF Margin = 26.06% (FCF TTM 921.7m / Revenue TTM 3.54b)
Net Margin = 18.40% (Net Income TTM 650.7m / Revenue TTM 3.54b)
Gross Margin = 29.83% ((Revenue TTM 3.54b - Cost of Revenue TTM 2.48b) / Revenue TTM)
Gross Margin QoQ = 35.68% (prev 22.24%)
Tobins Q-Ratio = 8.24 (Enterprise Value 59.9b / Total Assets 7.27b)
Interest Expense / Debt = 7.71% (Interest Expense 77.1m / Debt 999.9m)
Taxrate = 20.38% (166.4m / 816.8m)
NOPAT = 706.5m (EBIT 887.3m * (1 - 20.38%))
Current Ratio = 3.08 (Total Current Assets 1.61b / Total Current Liabilities 522.7m)
Debt / Equity = 0.20 (Debt 999.9m / totalStockholderEquity, last quarter 5.08b)
Debt / EBITDA = 0.17 (Net Debt 202.1m / EBITDA 1.20b)
Debt / FCF = 0.22 (Net Debt 202.1m / FCF TTM 921.7m)
Total Stockholder Equity = 6.37b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.82% (Net Income 650.7m / Total Assets 7.27b)
RoE = 10.21% (Net Income TTM 650.7m / Total Stockholder Equity 6.37b)
RoCE = 12.04% (EBIT 887.3m / Capital Employed (Equity 6.37b + L.T.Debt 996.5m))
RoIC = 10.75% (NOPAT 706.5m / Invested Capital 6.57b)
WACC = 13.02% (E(59.7b)/V(60.7b) * Re(13.14%) + D(999.9m)/V(60.7b) * Rd(7.71%) * (1-Tc(0.20)))
Discount Rate = 13.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.47 | Cagr: 0.15%
[DCF] Terminal Value 64.38% ; FCFF base≈805.6m ; Y1≈923.5m ; Y5≈1.36b
[DCF] Fair Price = 25.13 (EV 11.1b - Net Debt 202.1m = Equity 10.9b / Shares 435.5m; r=13.02% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 80.91 | EPS CAGR: 51.31% | SUE: 0.85 | # QB: 1
Revenue Correlation: 96.28 | Revenue CAGR: 21.98% | SUE: 0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.39 | Chg30d=+6.37% | Revisions=+0% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.35 | Chg30d=+7.88% | Revisions=+22% | Analysts=10
EPS current Year (2026-12-31): EPS=1.62 | Chg30d=+2.71% | Revisions=+27% | GrowthEPS=+12.8% | GrowthRev=-0.5%
EPS next Year (2027-12-31): EPS=2.66 | Chg30d=+0.35% | Revisions=-6% | GrowthEPS=+63.6% | GrowthRev=+13.8%
[Analyst] Revisions Ratio: +12% (up=21, down=16)